STOCK TITAN

Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Inspira Technologies (Nasdaq: IINN) announced the showcase of its FDA-cleared life-support system, the INSPIRA™ ART100, at the AmSECT 63rd International Conference in San Diego from March 19-23, 2025. The system, which received FDA 510(k) clearance in May 2024 for cardiopulmonary bypass procedures, will be displayed at distributor Glo-Med Networks' booth.

The conference, held at the Loews Coronado Bay Resort, provides a platform for leading perfusion professionals to experience Inspira's innovative extracorporeal circulation technology. The showcase represents an opportunity for the company to expand exposure of their technology within the perfusion community.

Loading...
Loading translation...

Positive

  • FDA 510(k) clearance received for INSPIRA ART100 system in May 2024

Negative

  • None.

News Market Reaction 1 Alert

-5.23% News Effect

On the day this news was published, IINN declined 5.23%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Leading perfusion professionals to experience Inspira's FDA-cleared cardiopulmonary bypass INSPIRA™ ART100 technology at premier industry event

RA'ANANA, Israel, March 19, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira," "Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration-cleared life-support system, the INSPIRA™ ART100, will be showcased at the American Society of Extracorporeal Technology (AmSECT) 63rd International Conference, taking place March 19-23, 2025, at the Loews Coronado Bay Resort in San Diego, California, by their distributor Glo-Med Networks Inc ("Glo-Med").

Inspira_Technologies_Logo

Conference attendees will have the opportunity to explore Inspira's cutting-edge cardiopulmonary bypass technology at Glo-Med's booth. The INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for use in cardiopulmonary bypass procedures, represents an advancement in extracorporeal circulation technology.

"The AmSECT International Conference brings together leading perfusion professionals, providing an ideal platform to showcase our INSPIRA ART100 system," said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. "This event offers an excellent opportunity to further expose our innovative technology to the perfusion community. We look forward to connecting with industry experts and demonstrating how our solutions can support medical professionals."

Visitors interested in scheduling a personal meeting are welcome to contact Mr. Levi Perryman at levi@glomednet.com or visit Booth number 4.

About AmSECT 63rd International Conference

The American Society of ExtraCorporeal Technology (AmSECT) International Conference is the premier global event for perfusion professionals, focusing on advancements in extracorporeal circulation, patient care, and perfusion education. The event will feature the latest medical technologies, research, and discussions shaping the future of perfusion.

About Inspira Technologies

Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART500 system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA ART500 (Gen 2), INSPIRA Cardi-ART, and HYLA blood sensor, are currently in development and have not yet received regulatory approval.

For more information, visit: https://inspira-technologies.com

Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

Capital Markets & Investor Contact
Arx | Capital Markets Advisors
North American Equities Desk
inspira@arxadvisory.com

Cision View original content:https://www.prnewswire.com/news-releases/inspira-technologies-innovative-life-support-system-to-be-showcased-at-amsect-63rd-international-conference-2025-in-san-diego-302405781.html

SOURCE Inspira Technologies

FAQ

When did the INSPIRA ART100 system receive FDA clearance for cardiopulmonary bypass procedures?

The INSPIRA ART100 system received FDA 510(k) clearance in May 2024 for use in cardiopulmonary bypass procedures.

Where and when will Inspira Technologies (IINN) showcase their ART100 system?

The INSPIRA ART100 system will be showcased at the AmSECT 63rd International Conference, taking place March 19-23, 2025, at the Loews Coronado Bay Resort in San Diego.

Which company is distributing the INSPIRA ART100 system at the AmSECT conference?

Glo-Med Networks Inc. is the distributor showcasing the INSPIRA ART100 system at the conference.

What is the primary application of IINN's INSPIRA ART100 system?

The INSPIRA ART100 system is designed for use in cardiopulmonary bypass procedures as a life-support system.
Inspira Technologies Oxy Bhn Ltd

NASDAQ:IINN

IINN Rankings

IINN Latest News

IINN Latest SEC Filings

IINN Stock Data

34.83M
33.47M
8.75%
4.39%
4.92%
Medical Devices
Healthcare
Link
Israel
Ra'anana